Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genmab ( (GMAB) ) just unveiled an update.
Following its Annual General Meeting on March 19, 2026, Genmab’s board reconstituted itself, appointing Deirdre P. Connelly as chair and Pernille Erenbjerg as deputy chair, underscoring a continued focus on experienced leadership in its global oncology franchise. The board also approved new long-term equity incentives, granting 5,213 restricted stock units and 4,485 warrants to employees and subsidiaries at a grant price aligned with Genmab’s market valuation, reinforcing retention and alignment with shareholder interests through multi-year vesting and performance-linked compensation structures.
Each restricted stock unit was issued cost-free with a fair value equal to the DKK 1,645.00 closing share price on the March 19, 2026 grant date and will vest after three years, subject to the company’s established RSU program conditions. The cost-free warrants, also struck at DKK 1,645.00 with a calculated fair value of DKK 530.62 under Black-Scholes, will vest after three years and remain exercisable for up to seven years, indicating Genmab’s continued use of equity-based rewards to attract and retain key talent in a competitive biotech labor market and align long-term incentives with share price performance.
The most recent analyst rating on (GMAB) stock is a Hold with a $29.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, it has built a broad portfolio of antibody-based therapeutic formats, including bispecifics, ADCs and immune-modulating antibodies, powering eight approved medicines and a strong late-stage clinical pipeline across global markets.
Average Trading Volume: 1,704,640
Technical Sentiment Signal: Sell
Current Market Cap: $15.89B
See more insights into GMAB stock on TipRanks’ Stock Analysis page.